Evidence map›Paper›PMID 35124731›Full record

SynthesisClinical oral investigations2022

Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy.

Bassel Traboulsi-Garet, Adrià Jorba-García, Octavi Camps-Font, Fabio Abreu Alves, Rui Figueiredo, Eduard Valmaseda-Castellón

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Clinical oral investigations, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bassel Traboulsi-GaretOral Surgery and Implantology, Faculty of Medicine and Health Sciences, University of Barcelona, Campus de Bellvitge, C/ Feixa Llarga, s/n; Pavelló Govern, despatx 2.9., 08907 , L'Hospitalet de Llobregat, Barcelona, Spain.
Adrià Jorba-GarcíaOral Surgery and Implantology, Faculty of Medicine and Health Sciences, University of Barcelona, Campus de Bellvitge, C/ Feixa Llarga, s/n; Pavelló Govern, despatx 2.9., 08907 , L'Hospitalet de Llobregat, Barcelona, Spain.
Octavi Camps-FontOral Surgery and Implantology, Faculty of Medicine and Health Sciences, University of Barcelona, Campus de Bellvitge, C/ Feixa Llarga, s/n; Pavelló Govern, despatx 2.9., 08907 , L'Hospitalet de Llobregat, Barcelona, Spain.
Fabio Abreu AlvesStomatology Department - A.C. Camargo Cancer Center, Sao Paulo, Brazil.
Rui FigueiredoOral Surgery and Implantology, Faculty of Medicine and Health Sciences, University of Barcelona, Campus de Bellvitge, C/ Feixa Llarga, s/n; Pavelló Govern, despatx 2.9., 08907 , L'Hospitalet de Llobregat, Barcelona, Spain. ruibarbosa@ub.edu.ORCID http://orcid.org/0000-0002-2122-6530
Eduard Valmaseda-CastellónOral Surgery and Implantology, Faculty of Medicine and Health Sciences, University of Barcelona, Campus de Bellvitge, C/ Feixa Llarga, s/n; Pavelló Govern, despatx 2.9., 08907 , L'Hospitalet de Llobregat, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the usefulness of Serum C-terminal telopeptide cross-link of type 1 collagen (sCTX) as a preoperative marker for predicting the risk of developing medication-related osteonecrosis of the jaws (MRONJ) after invasive oral surgery in patients on antiresorptive medication. MATERIALS AND

methodsTwo authors independently searched four electronic databases up to March 25, 2021, for case-control studies and prospective and retrospective cohort studies that assessed preoperative sCTX levels in patients taking antiresorptive medication who underwent oral surgery procedures. The main outcome was the number of MRONJ cases in patients with an sCTX value lower and higher than 150 pg/mL. Qualitative and quantitative data was extracted in tables and the risk of bias was assessed using the QUADAS-2 tool. Estimates of diagnostic accuracy were expressed as sensitivity, specificity, negative and positive likelihood ratio (LR - and LR +), and diagnostic odds ratio (DOR), with a 95% confidence interval (95%CI). The data were combined using random-effects models based on the inverse variance method.

resultsSeven studies were included in the meta-analysis. The results were as follows: sensitivity 57% (95%CI: 41-71%), specificity 72% (95%CI: 64-79%), LR + 2 (95%CI: 1.3-3.1), LR - 0.6 (95%CI: 0.4-0.9), and DOR 3.4 (95%CI: 1.5-7.7).

conclusionsThe low overall performance of sCTX indicates that this parameter is not suitable for predicting MRONJ risk in patients on antiresorptive medication who need an oral surgery procedure. CLINICAL RELEVANCE: sCTX should not be considered a reliable preoperative marker to predict MRONJ development.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsCollagen Type IDiagnostic Tests, RoutineDiphosphonatesHumansJawProspective StudiesRetrospective StudiesRisk FactorsBone Density Conservation AgentsCollagen Type IDiphosphonatesBisphosphonate-associated osteonecrosis of the jawBone turnover markersCTXJaw diseasesMedication-related osteonecrosis of the jawOsteonecrosis

Identifiers

PMID35124731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.